Abstracts / posters

 

Product Conference Title Download
BI-505 55th ASH Annual Meeting and Exposition, December 7-10, 2013, New Orleans, USA

Macrophages activation by ICAM1 antibody combined with lenalidomide has enhanced anti-myeloma activity in a supportive microenvironment in vivo and in vitro

PDF Icon
BI-505 14th International Myeloma Workshop, April 3-7, 2013, Kyoto, Japan

A Phase I, Dose Escalation Study of BI-505 in
Relapsed/Refractory Multiple Myeloma

PDF Icon
BI-505 53rd ASH Annual Meeting, December 10-13, 2011, San Diego, USA The effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells PDF Icon
TB-402 57th Congress of the International Society on Thrombosis and Haemostasis, July 23-27, 2011, Kyoto, Japan Partial vs complete FVIII inhibition in a mouse model of venous thrombosis PDF Icon
TB-402 57th Congress of the International Society on Thrombosis and Haemostasis, July 23-27, 2011, Kyoto, Japan Effects of a FVIII inhibitor TB-402 on coagulation: reversibility with pro-coagulants PDF Icon
BI-505 102nd AACR Annual Meeting, April 2-6, 2011, Orlando, FL, USA Cell death-inducing ICAM-1 antibody has broad and potent anti-myeloma activity in vivo PDF Icon
BI-505 13th International Myeloma Workshop, May 3-6, 2011, Paris, France

The epitope targeted by cell death-inducing ICAM-1 antibody BI-505 is highly expressed in multiple myeloma

PDF Icon
TB-402 21st International Congress on Thrombosis: July 6-9, 2010, Milan, Italy Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery PDF Icon
TB-403 AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics in Boston, MA, USA, Nov 09 A phase I, dose escalation study of TB-403 in patients with solid tumors pdf
TB-403 AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics in Boston, MA, USA, Nov 09 A first-in-man, phase I, dose escalation study of TB-403 in healthy male subjects pdf
TB-402 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Georgia, USA, Dec 2007 A Human Monoclonal Antibody Partially Inhibiting FVIII Activity: A Novel, Long-acting Antithrombotic Drug pdf